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Abstract
Background: The epidemiology of methicillin-resistant
Staphylococcus aureus (MRSA) has dramatically changed over
the last decade by the emergence of community-associated
MRSA (CA-MRSA). Recent studies indicate that these strains
have already spread to hospitals. To evaluate if SCCmec type
IV and Panton–Valentine leukocidin (PVL) are unambiguous
markers of CA-MRSA, we analyzed 77 sporadic MRSA strains
isolated, in our low MRSA incidence university hospital, from
inpatients between 2000 and 2004.
Methods: MRSA strains were analyzed by staphylococcal
cassette chromosome mec (SCCmec) typing, PCR for PVL
genes and pulsed-field gel electrophoresis (PFGE). MRSA was
classified in HA-MRSA or CA-MRSA according to Centers for
Disease Control and Prevention (CDC) criteria. Antimicrobial
susceptibility testing was performed using microbroth dilu-
tion method following CLSI recommendations.
Results: Among 77 sporadic single-patient strains, SCCmec
types I–IV and four subtypes were identified. Type IV/IVA was
most common (42.9%).The distribution of SCCmec types
changed over the years. Type IV/IVA strains increased from
33.3% in 2000 to 57.9% in 2004. Type IV strains were resis-
tant to ciprofloxacin in 81.8%, and in 9.1% to tobramycin
while type IVA strains were 100% resistant to both antimi-
crobials. In contrast, non-type IV/IVA strains were resistant
to ciprofloxacin in 86.4%, and in 75.0% to tobramycin. Only
one strain was PVL positive and harbored SCCmec type III
variant. By PFGE analysis, the 33 SCCmec type IV/IVA strains
comprised 12 distinct genotypes. 36.4% of 11 CA-MRSA and
43.9% of 66 HA-MRSA harbored SCCmec type IV/IVA.
Conclusion: Type IV/IVA has become the most common
SCCmec type in inpatients of our university hospital. The
SCCmec type IV/IVA is present in both CA-MRSA and HA-MRSA
limiting its use as a marker for CA-MRSA.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) has
become the most important emerging pathogen worldwide.
Methicillin resistance in staphylococci is caused by the
expression of penicillin-binding protein 2a (PBP2a)
encoded by the mecA gene that is located on a genetic
element called the staphylococcal cassette chromosome
(SCC). SCCmec is a mobile DNA element of 21–67 kb
and is integrated into the chromosome of MRSA [1, 2].
Hospital-associated MRSA (HA-MRSA) isolates are
typically resistant to multiple antibiotics, negative for
Panton–Valentine leukocidin (PVL) encoding genes and
primarily harbor SCCmec types I, II, III, and rarely IV [1,
3, 4]. Up to six main types of SCCmec and many variants,
especially of type IV are known [1, 5, 6]. Type IV is
present in many more genetic backgrounds than other
types suggesting an enhanced mobility [7–9]. In contrast
to HA-MRSA, community-associated MRSA (CA-
MRSA) strains are commonly susceptible to the majority
of non-b-lactam antibiotics, frequently expressing genes
encoding for PVL and are predominantly of the SCCmec
types IV and V, and present multiple patterns by pulsed-
field gel electrophoresis [10, 11].
Recently, the emergence of CA-MRSA dramatically
increased the importance and awareness of this multire-
sistant pathogen [12]. In contrast to HA-MRSA, CA-
MRSA infections typically occur in young, athletic and
healthy individuals without exposure to healthcare
institutions [13].
The University Hospital Basel (UHB), Basel,
Switzerland, has a low overall incidence of MRSA, between
0.104 and 0.179 per 1,000 patient days with very rare clusters.
On average, less than two bloodstream infections with
MRSA per year are observed in a setting with more than 700
episodes of bloodstream infections per year. This environ-
ment allows testing the hypothesis, if SCCmec type IV and
PVL are markers of CA-MRSA among strains found in
hospitalized patients. We, therefore, compared the presence
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of these molecular traits with epidemiological data obtained
from inpatients between 2000 and 2004.
Patients and Methods
Epidemiological Data and Setting
Since 1996, demographic data of all patients admitted to the
UHB and colonized or infected with MRSA were prospectively
collected in a case report form, and data transferred to a data-
base (MS Access, USA). MRSA was classified as CA-MRSA or
HA-MRSA according to Centers for Disease Control and
Prevention (CDC) criteria [14]. Since 1992, the hospital follows a
‘‘search and destroy’’ policy, adapted from guidelines issued by
the Dutch Infection Control Society [15]. Our approach was
successfully validated in a foreign hospital [16]. Patients with risk
factors or those previously colonized or infected with MRSA are
routinely screened on admission by swabs of nose, throat, and
any wounds present [21]. Since 1992, MRSA strains are saved at
–70 C. All consecutive single patient isolates of hospitalized
patients between 2000 and 2004 were included in this study.
Strains from outpatients and from epidemics or clusters were
excluded. Only one isolate per patient was analyzed.
Bacterial Strains and Susceptibility Testing
Methicillin-resistant Staphylococcus aureus isolates were detected
by standard culture methods. Colonies suspected to be Staphylo-
coccus aureus were screened with the latex agglutination test
PASTOREX STAPH PLUS (BIO-RAD, France) and confirmed
as such with Gram stain, catalase, and aurease (Rapidec staph,
bioMe´rieux, France). Resistance to oxacillin was determined
according to the guidelines of the Clinical and Laboratory Standards
Institute (CLSI), formerly NCCLS (http://www.clsi.org), using an
oxacillin disk and/or screen agar (MRSA Screen Agar, bioMe´rieux)
and confirmed by the detection of penicillin-binding protein 2a
(MRSA-Screen, Denka Seiken, Japan). Any discrepant results
were resolved by PCR testing using primers targeting femA and
mecA gene. The susceptibility against 12 antimicrobial compounds
was tested using microbroth dilution method (MicronautTM system,
Merlin, Germany) following CLSI recommendations.
SCCmec Typing
The SCCmec multiplex PCR assay was performed according to
the method of Oliveira and de Lancastre [17] with modifications
in the primer concentrations. Concentrations for primers were as
follows: 0.25 lM for CIF2 F2, CIF2 R2, MECI P2, MECI P3,
RIF5 F10, RIF5 R13; 0.3 lM for IS431 P4, pUB110 R1; 0.5 lM
for pT181 R1; 1.0 lM for DCS F2, DCS R1, RIF4 F3, RIF4 R9,
MECA P4, MECA P7 and 1.7 lM for KDP F1, KDP R1. The
multiplex PCR included eight loci (A–H) [17]. MRSA strains
NCTC10442, N315, 85/2082, and WSPP A were included as
controls for SCCmec types I, II, III, and IV, respectively. PCR
products were resolved by electrophoresis and visualized with
ethidium bromide on 2% agarose gels.
PVL
The PVL genes (lukS-PV, lukF-PV) were detected by PCR
according to the method of Lina et al. [18]. The PCR products
were visualized with ethidium bromide on 1.5% agarose gels.
Pulsed-Field Gel Electrophoresis
All isolates were analyzed by pulsed-field gel electrophoresis
(PFGE) as described previously [19]. After SmaI digestion
the DNA restriction fragments were separated by PFGE and
dendrograms were drawn using the software GelCompar 4.5
(Applied Maths, Belgium). The fragment patterns were inter-
preted according to the criteria of Tenover et al. [20].
Results
A total of 187 single patient isolates were recorded in the
database from inpatients, outpatients, and healthcare
workers from 2000 to 2004. Among 104 MRSA strains
isolated from inpatients, 93 were available for the analysis
by SCCmec typing, by PVL and PFGE; 11 strains were
accidentally disposed or were not viable anymore; 17.2%
(16/93) of the strains originated from an MRSA epidemic
and were therefore excluded. Fourteen of these isolates
possessed the SCCmec type I and two isolates type IVA.
Among the remaining 77 sporadic cases, the SCCmec type
IV/IVA was the most common representing 42.9% of
cases (Figure 1). The rate of SCCmec type IV/IVA strains
increased from 33.3% in 2000 to 57.9% in 2004 (Figure 2).
The incidence density of MRSA by inpatients increased in
the same period from 0.104 to 0.165 per 1,000 patient days
(Figure 2).
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Figure 2. Percentage of SCCmec type IV/IVA strains and the
incidence density of MRSA in inpatients per 1,000 patient days.
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Figure 1. Prevalence of SCCmec types over a 5-year period in
percentage. The bar labeled with IV/IVA comprises SCCmec type IV
(gray) and type IVA (hatched).
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Nine different SCCmec types and subtypes were
detected (Figure 1; Table 1).
From the 77 analyzed strains, 11 (14.3%) were
classified as CA-MRSA, 66 (85.7%) as HA-MRSA. Of
CA-MRSA and of HA-MRSA, 36.4% and 43.9% har-
bored SCCmec type IV/IVA, respectively. The rate of
type IV/IVA strains by HA-MRSA increased from 33.3%
to 66.7%. Surprizingly, only one strain classified as
HA-MRSA was positive for PVL (Table 1).
By PFGE analysis, the 33 SCCmec type IV/IVA
strains comprised 12 distinct genotypes (Figure 3). 24.2%
of these strains originated from the infected and 75.8%
from colonized patients.
The most discriminating antimicrobial resistance rates
among SCCmec type IV, IVA and non-type-IV are given
in table 2.
Discussion
In our setting, the low incidence of MRSA coupled with a
prospective active screening program using a standardized
case report form provided a unique opportunity to classify
MRSA patients with epidemiological data and results
from molecular typing [21].
From the 77 sporadic cases, 11 (14.3%) were
CA-MRSA and 66 (85.7%) HA-MRSA. SCCmec type
IV/IVA was already common in the year 2000 and has
become the most common type with 57.9% prevalence in
2004. PFGE analysis of the 33 SCCmec types IV/IVA
isolates comprised 12 distinct genotypes. Several strains
had similar PFGE patterns, but were epidemiologically
unrelated. They were isolated from different years and/or
different locations, suggesting an epidemic clone in the
community. Similar to a recent observation in Chicago, it
Table 1
Definitions of SCCmec types and subtypes.
SCCmec type I IA II III IV IVA Type III
variant
New
variant
New
variant
Only mec
Locus A, D A, G, D D, B, C F, H, E, C D G, D F, E A, F, E F, D
No. of isolates 14 1 15 6 22 11 5 1 1 1
No. of PVL positive isolates 0 0 0 0 0 0 1 0 0 0
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appears that SCCmec type IV/IVA has spread in the
hospital without evidence for clusters or epidemics [22].
In contrast to the study of Popovich [22], who exclu-
sively collected strains from invasive bloodstream infec-
tions, only 24% of patients in our study were infected with
MRSA rather than colonized. About 43.9% of HA-
MRSA and 36.4% of CA-MRSA were of SCCmec type
IV/IVA. In USA, HA-MRSA primarily harbors SCCmec
types I, II, III, and occasionally IV and CA-MRSA are
predominantly of the SCCmec type IV [11]. In Geneva,
another Swiss town, the most frequent MRSA strains
were of SCCmec type I (86%) followed by type IV (11%),
whereas other types were detected only on rare occasions
[25]. However, similar to our observation, the number of
type IV isolates has considerably increased during the last
years [23]. The latter study analyzed a highly selective
strain collection of non-multidrug-resistant and commu-
nity-acquired MRSA, including those from epidemics. In
contrast, our study used all consecutive strains from hos-
pitalized patients. Other authors also reported an increase
of SCCmec type IV in the hospital setting [24]. To sum-
marize, MRSA harboring genetic markers of CA-MRSA
have increased over the past years at our hospital and
appear to replace traditional hospital MRSA strains.
Bootsma et al. [26] already predicted in their model that
CA-MRSA strains would replace, not add to, traditional
HA-MRSA strains. Data from our study and those by
Popovich support this model [22].
The strength of our study is the unique environment
of the hospital: less than 0.5% of all patients admitted to
the hospital are colonized with MRSA, as reported by
Mertz et al. [21] and confirmed by a recent screening of
1,000 patients on admission (data not shown). In addition,
the surveillance program identifies only between 2 and 10
transmissions per year in our 750-bed tertiary care hos-
pital. Therefore, patients are very unlikely to be misclas-
sified as sporadic when they were in fact part of a cluster.
Replacement of traditional hospital-associated MRSA
strains with CA-MRSA strains would have serious infec-
tion-control implications in a low-prevalence setting; it
may render infection control activities futile if multiple
clusters of CA-MRSA spread in the hospital with
unknown modes of transmission. Cross-transmission of
CA-MRSA and familial transmissions have been
documented earlier [27]. The MRSA low incidence
countries could use another strategy for the control of
MRSA, if the prevalence of MRSA is growing despite the
fact that hospital-associated cases are under control.
The search and destroy policy of our institution may
have successfully controlled HA-MRSA, likely overrep-
resenting type IV by eliminating type I and type II strains
[14].
Similar to Qi et al., our isolates of SCCmec type IV
were mostly resistant to ciprofloxacin and clarithromycin
[28]. The SCCmec type IVA strains were more resistant
than type IV in our setting. In contrast to the study results
of USA, we had only one PVL positive strain [11]. This
may be due to the predominance of colonized patients in
our data set, exclusion of outpatients or differences be-
tween the rates of different countries or the time frame of
data collection [29]. In fact, few PVL positive strains by
SCCmec type IV (12%) have also been found in Zurich,
Switzerland [28]. In our setting, PVL did not prove to be a
reliable marker for CA-MRSA.
In conclusion, we have demonstrated that SCCmec
type IV/IVA is present in both CA-MRSA and HA-
MRSA, limiting its use as a marker for CA-MRSA. The
epidemiology of MRSA in hospitals is rapidly changing,
and MRSA SCCmec type IV may become the most
common type in hospitals in near future.
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